Named patient access to olverembatinib
Treatments studied
This program provides access to olverembatinib (also known as HQP1351) for patients who have no other treatment options and whose doctor believes the drug might help. The drug is given to patients individually under a special access program, not as part of a formal clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your doctor must believe that olverembatinib may help you and that you are suitable to receive it.
- You must not have had a recent heart attack, stroke, or blood clots in your legs, lungs, or eyes.
- You must not have serious heart problems, such as heart failure or coronary artery disease.
- You must not have severe liver problems, severe low blood cell counts, or active bleeding.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a drug called olverembatinib is processed by the body in people with different levels of liver impairment. It looks at how the liver condition affects the drug levels and safety, which may help find the right dose.
This trial studies olverembatinib to treat certain blood cancers that have an FGFR1 rearrangement (a specific gene change). It’s for people whose disease is newly diagnosed, has progressed, or has come back, and who can safely take the study medicine and attend follow-up visits.
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
This study tests a new targeted drug called olverembatinib for people with chronic myeloid leukemia (CML) that has stopped responding to other treatments. It aims to see if the drug can control the leukemia with fewer side effects.
This study looks at whether lowering the dose of olverembatinib (from 30 or 40 mg to 20 mg every other day) keeps working well for people with chronic myeloid leukemia who have already had a good response. It aims to see if a lower dose can still control the cancer while possibly reducing side effects.
This trial tests the drug olverembatinib alone for people with newly diagnosed chronic phase CML who have not had much prior treatment. It aims to see how well the drug works and what side effects it may cause.